1526-1527 / 2063
Predictive biomarkers for cetuximab in HNSCC?
Bonner J Oncologist 2017;22:811
Patients with p16+ tumors had
superior OS than those with p16-
tumors in both the cetuximab +
RT arm and RT alone treatment
arm.
Although the treatment effects
were stronger in the p16+
subgroup, interaction tests
revealed no significant interaction
between p16 status and
treatment